Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07347925
Recruiting Observational

Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF

NCT07347925 · tracked via the Priya Life Science Egypt tracker
Sponsor
Future University in Egypt
Phase
Observational
Started
2026-01-10
Last updated
2026-01-16

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

Prehospital ARNI useNo prehospital ARNI use

Prehospital ARNI use: Participants who were using ARNI therapy before hospital admission

No prehospital ARNI use: Participants who were not using ARNI therapy before hospital admission

Study summary

This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before hospital admission affects short-term health outcomes.

The study will compare two groups of participants: those who were already taking ARNI before coming to the hospital and those who were not. Information will be collected from medical records during the hospital stay, including heart-related events, kidney-related events, and how long participants stay in the hospital.

Some participants will also be followed for a short period after discharge. This study may help improve understanding of outcomes associated with ARNI use in people with heart failure in routine clinical care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * \>= 18 years, male or female EF \<40% Exclusion Criteria: * EF\>40% Pregnancy or breastfeeding

Primary outcome measure(s)

  • In-hospital cardiac and renal events — 3 months

Trial sites (1)

FacilityCityRegionStatus
Mansoura university Hospital Al Mansurah Egypt Recruiting

More Future University in Egypt trials in Egypt

Clinical and Electromyographic Assessment of Occlusal Splint Therapy Recruiting
Evaluation of Different Grafting Technique of Thin Gingival Phenotype With Delayed Dental Implants Recruiting
Evaluation of Post-operative Pain and Bacterial Load Reduction After Application of Three Intra-canal Medications (Cocoa Husk Versus Calcium Hydroxide With and Without Cocoa) in Necrotic Mandibular First Molar. Active, not recruiting
Evaluation of the Clinical Performance of a Bulk Fill Resin Composite in Cuspal Coverage Restorations of Vital Posterior Teeth (RCT) Active, not recruiting
The Effect of XP-Endo Finisher Activation of Bioceramic Sealer on Postoperative Pain in Mandibular First Molar With Symptomatic Irreversible Pulpitis Recruiting

Other trials for the same condition

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction Recruiting
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases Recruiting
Effect of Add-on L-Arginine Therapy on Heart Failure Patients Starting soon
AI-Based Personalized Self-Management for Patients With Heart Failure Starting soon
the Clinical Outcome of Empagliflozin in Pediatric Heart Failure Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07347925 on ClinicalTrials.gov ↗ ← All trials in Egypt